Dr. Fernando C. Trespalacios, MD

Dr. Trespalacios practices at Bma Metropolitan in Miami, Florida.

Dr. Trespalacios' NPI, 1710969688, was assigned on November 16, 2005. Dr. Trespalacios graduated from Universidad Central del Caribe School of Medicine in 1995. Dr. Trespalacios holds Florida license ME91609.

Dr. Trespalacios' primary practice is Bma Metropolitan, at 9193 SW Sunset St, Miami, FL 33173 in Miami-Dade County. The practice phone is (786) 388-1305.

Dr. Trespalacios' primary practice is Bma Metropolitan in Miami, Florida. Dr. Trespalacios is also affiliated with Jackson Memorial Hospital. The medical group on file is Kidney Specialists in Miami. Dmand AI also links Dr. Trespalacios to 4 more hospitals, 4 dialysis centers and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Trespalacios practices, 10 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Trespalacios' primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Trespalacios is board certified in nephrology by the American Board of Internal Medicine. Dmand AI has Dr. Trespalacios' licenses on file in 3 states: Florida, Hawaii and Maryland.

Dmand AI lists acute kidney failure, chronic kidney disease, fluid and electrolyte imbalances and kidney cysts among the conditions Dr. Trespalacios treats.

CMS data shows 1,670 Medicare services from Dr. Trespalacios across 12 procedure codes in 2024, for 595 Medicare patients. Medicare paid $198,060 for them.

CMS counts 595 Medicare patients who saw Dr. Trespalacios in 2024. The largest group is 75 to 84, with 212 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 51% are also on Medicaid. Their average risk score is 4.43, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Trespalacios' median patient age at 75, with 48% women.

In 2024, Dr. Trespalacios wrote 2,111 Medicare Part D claims for 348 patients. 72% of them were for generic drugs. CMS names the drug for 1,819 of them, across 50 drugs with 11 or more claims each, at $633,985 in total drug cost. In 2023, CMS named 2,151 claims across 53 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Trespalacios for performance year 2024, reported individually. Dr. Trespalacios accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Trespalacios as offering telehealth.

Dmand AI links 11 papers to Dr. Trespalacios, published from 2003 to 2010. 2003 was the busiest year, with 2. The most frequent topics are Kidney Failure, Chronic, Renal Dialysis and Angiotensin-Converting Enzyme Inhibitors. Dr. Trespalacios has published most often in Infect Immun. Dr. Trespalacios' most frequent co-authors are Tejinder Singh Ahuja, MD, Christopher W. Glanton, MD and Edward J. Gorak, DO.

CMS Open Payments shows 318 general payments to Dr. Trespalacios from 33 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,132.

Dmand AI lists 2 awards for Dr. Trespalacios.

Dr. Trespalacios graduated from Universidad Central del Caribe School of Medicine in 1995.

Dr. Trespalacios is in network with 17 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.